Skip to main content

Celgene said to be near $7 billion deal to buy Impact Biomedicines

Celgene Corp. is nearing a deal to buy biotechnology company Impact Biomedicines for as much as $7 billion, according to people familiar with the matter.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.